autologous engineered skin substitute

Cell therapyexperimental

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2016 (NCT01655407)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    Tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • autologous engineered skin substitute

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01655407Phase 2Sep 1, 2016Amarantus BioScience Holdings, Inc., Amarex Clinical Research, University of Arizona
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Amarantus BioScience Holdings, Inc.For profit1112016
Amarex Clinical ResearchFor profit1012016
University of ArizonaAcademic/Hospital1012016
3 organizations
Page 1 / 1